SynthesisFrontiers in endocrinology2022
Prevalence of polycystic ovary syndrome in patients with type 2 diabetes: A systematic review and meta-analysis.
Synthesis in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Treatment and complications of PCOS in adolescents - what's new in 2023?Frontiers in endocrinology · 2024Pooled it
- Redox biology in PCOS: Biomarkers, mechanistic networks, and targeted interventions (Review).International journal of molecular medicine · 2026Review
- Hormonal and metabolic profiles in teenagers and young adults with polycystic ovary syndrome (PCOS).Endocrine · 2026Article
- Exploring the comorbidity of type 2 diabetes mellitus and polycystic ovary syndrome: treatment with traditional Chinese medicine.Frontiers in medicine · 2026Review
- Upregulation of PLAU in granulosa cells disrupts steroid hormone synthesis and promotes apoptosis by activating NF-κB signaling pathway in PCOS.Journal of ovarian research · 2025Article
- The effect of type 2 diabetes genetic predisposition on non-cardiovascular comorbidities.Nature communications · 2025Article
- Global trends in polycystic ovarian syndrome over 30 years: an age-period-cohort study of 204 countries and territories (1990-2021).Journal of health, population, and nutrition · 2025Article
- The effect of type 2 diabetes genetic predisposition on non-cardiovascular comorbidities.medRxiv : the preprint server for health sciences · 2025Article
- Metformin in polycystic ovary syndrome: unraveling multi-stage therapeutic mechanisms from puberty to long-term health outcomes.Frontiers in pharmacology · 2025Review
- Exploring the Combination of Traditional Chinese and Allopathic Medicine in the Treatment of Polycystic Ovary Syndrome from the Perspective of Modern Medicine.Drug design, development and therapy · 2025Review
- Article
- MicroRNAs as Biomarkers for Metabolic Disorders in Polycystic Ovary Syndrome (PCOS): A Review.Medical science monitor : international medical journal of experimental and clinical research · 2024Review
- Article
- Pregnancy outcomes in type 2 versus type 1 diabetes: systematic review with meta-analyses.Endocrine connections · 2024Article
- Vitamin D has therapeutic effects on obesity and hyperandrogenemia in PCOS mouse model induced by low dose DHEA and high-fat diet.BMC women's health · 2024Article
- Gonadal dysfunction in women with diabetes mellitus.Endocrine · 2024Review
- Association between Coffee Consumption and Polycystic Ovary Syndrome: An Exploratory Case-Control Study.Nutrients · 2024Article
- View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex-Related Differences.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Molecular Mechanisms in the Etiology of Polycystic Ovary Syndrome (PCOS): A Multifaceted Hypothesis Towards the Disease with Potential Therapeutics.Indian journal of clinical biochemistry : IJCB · 2024Review
- The "Asthma-Polycystic Ovary Overlap Syndrome" and the Therapeutic Role of Myo-Inositol.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: With type 2 diabetes mellitus (T2DM) occurring at a younger age, a greater number of women with T2DM experience reproductive health problems. The prevalence of polycystic ovary syndrome (PCOS), a common reproductive disease associated with T2DM, remains unknown in women with T2DM. This systematic review and meta-analysis aimed to determine the prevalence of PCOS in women with T2DM. Methods: Stata 15.1 was used to perform a meta-analysis on the prevalence of PCOS in patients with T2DM included in this study. Additionally, a narrative review of the effects of different diagnostic methods, obesity, state, and other factors on the prevalence of PCOS was conducted. Results: Meta-analysis showed that the overall prevalence of PCOS in women with T2DM was approximately 21%. Subgroup analysis showed that the incidence of PCOS in female patients aged 25-45 years was higher than that in female patients aged < 25 years. The prevalence of PCOS in obese women was 14%, which was lower than that in normal weight women and normal weight or overweight or obese women. Women with T2DM in Oceania had the highest incidence of PCOS, followed by those in Europe and Asia; women with T2DM in North America had the lowest incidence. In terms of PCOS diagnostic standards, the prevalence of PCOS diagnosed by the National Institutes of Health was the lowest. The prevalence of PCOS diagnosed on the basis of clinical symptoms and biochemical characteristics was the highest, and the prevalence of PCOS diagnosed on the basis of medical records was 20%. Conclusions: PCOS is a common disease in female patients with T2DM. The prevalence of PCOS in women with T2DM at childbearing age was higher than that in adolescent females. Women with T2DM at childbearing age should pay attention to the screening and prevention of PCOS to avoid the hazards of PCOS to reproductive health. Systematic review registration: PROSPERO, identifier CRD42022318657.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.